Phase Ib, international, dose escalation study to evaluate the safety, pharmacokinetics and efficacy of ST-617 for the attenuation of oral mucositis in patients receiving chemoradiation for head & neck cancer
Latest Information Update: 15 Dec 2023
At a glance
- Drugs ST 617 (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Acronyms ST617-101
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 15 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress